Samir Malhotra

Samir Malhotra currently serves as a Partner at Civilization Ventures and holds Board Observer positions at QUiCKR Bio, Tacit Therapeutics, and Range Biotechnologies, all since January 2024. Previously, Samir was the Founding COO of Replace Therapeutics from February 2022 to January 2024, during which the company was acquired by Tome Biosciences. Prior roles include Founding Head of Strategy and Operations at Rewrite Therapeutics, which was acquired by Intellia Therapeutics, and contributing to Business Operations and Strategy at Jazz Pharmaceuticals. Earlier experience includes working in Strategy Consulting at IQVIA and as a Research Associate at Stanford University School of Medicine. Samir's academic background includes education from Stanford University and Thousand Oaks High School.